RPM | REQUIREMENTS AND POLICIES MANUAL

    Title:

    Conflict of Interest in Research – CRADAs and non-Federal SPPs

    Publication date:

    12/11/2025

    Effective date:

    12/11/2025

    BRIEF

    Policy Summary

    Each Berkeley Lab employee participating in the negotiation, approval, execution or performance of a Cooperative Research and Development Agreement (CRADA) or non-Federal Strategic Partnership Project (SPP) must disclose a financial interest in any entity, other than the University of California, that has an interest in the CRADA or SPP. No Berkeley Lab employee shall have a substantial role (including an advisory role) in the negotiation, approval or performance of a CRADA or SPP, if, to such employee's knowledge they, or their near relative, holds a significant financial interest in any entity, other than the University of California, that has a substantial interest in the entity of the CRADA or SPP, unless approved in advance by the Department of Energy (DOE) Contracting Officer.

    Who Should Read This Policy

    This policy primarily affects employees who have any involvement in CRADAs and SPPs.

    To Read the Full Policy, Go To:

    The POLICY tab on this wiki page

    Contact Information

    Research Compliance Office
    [email protected]

    Title:

    Conflict of Interest in Research – CRADAs and non-Federal SPPs

    Publication date:

    12/11/2025

    Effective date:

    12/11/2025 

    POLICY

    A. Purpose

    Lawrence Berkeley National Laboratory (Berkeley Lab) must ensure that the financial interests of its employees do not present a conflict of interest in the negotiation, approval, or execution of a CRADA or non-Federal SPP.

    B. Persons Affected

    This policy applies to employees involved in the negotiation, approval, or execution of a CRADA or non-Federal SPP.

    C. Exceptions

    The DOE contracting officer may approve exceptions. Contracting officer approval is not required for SPPs from US federal, state, or public universities.

    D. Policy Statement

    1. Each employee who has a Substantial Role  in the negotiation, approval, execution or performance of a CRADA or non-Federal SPP, typically the principal investigator (PI), Co-PI, other significant contributors, division director or designee, Strategic Partnerships Office (SPO) Manager, SPO Contracts Officer, Licensing Manager and Intellectual Property Office reviewer if applicable, must disclose significant financial interests in any entity that has a substantial role in the CRADA or SPP.
    2. Disclosures are required for all new and amendment CRADA and SPP proposals for both direct and prime sponsors.
    3. The Research Compliance Office will review all disclosures of financial interest in a CRADA or SPP. If an employee holds a significant financial interest in an entity related to the CRADA or SPP, the employee must not have a Substantial Role (including an advisory role) in the negotiation, approval, execution, or performance of the CRADA or SPP until and unless the interest has been reviewed and an acceptable conflict of interest plan has been implemented.
    4. For CRADAs and SPP in which the partner is providing funds to Berkeley Lab, the Political Reform Act of 1974 also applies. The California Political Reform Act (CPRA) of 1974 and UC Policy require a principal investigator who proposes or conducts a research project or who receives a gift funded by a nongovernmental agency to disclose financial interests in the sponsor at the time of proposal submission or receipt of the gift using the Statement of Economic Interests for Principal Investigators (California Form 700-U). Financial thresholds for these disclosures may be lower than Significant Financial Interests as defined elsewhere in this policy. Research sponsored by US public universities and certain non-profit organizations is exempt from these requirements.

    E. Roles and Responsibilities

    Each employee who has a Substantial Role (including an advisory role) in the negotiation, approval, execution, or performance of a CRADA or SPP is required to disclose significant financial interests in any entity that has a substantial role in the CRADA or SPP by completing a CRADA and non-Federal SPP disclosure form. Principal Investigators and co-PIs must also complete a 700-U form disclosing financial interests in the sponsor of the research, unless the sponsor is a US governmental agency or public university, or is otherwise exempt from CPRA requirements. 

    The Research Compliance Office manages the review process for disclosures of financial interest related to CRADAs and SPPs, and coordinates review by the DOE contracting officer of any such disclosures as needed.

    F. Definitions

    Term  Definition

    Direct Sponsor

    Direct provider of funds to the institution. Example: Genentech receives funds from the Public Health Service for a study, and provides some of those funds to Berkeley Lab to conduct a specific part of the study. Genentech is the Direct Sponsor.

    Prime Sponsor

    Originating source of funds provided to the institution. Example: Genentech receives funds from the Public Health Service for a study, and provides some of those funds to Berkeley Lab to conduct a specific part of the study. The Public Health Service is the Prime Sponsor.

    Substantial Role

    Any individual responsible (including in an advisory role) for the negotiation, approval, execution, or performance of work conducted or to be conducted under an CRADA or non-federal SPP. This typically includes the principal investigator, co-investigators, any other research personnel considered essential to performance of the work, the division director, the contracting officer, SPO manager, and any other individual who is responsible for negotiating, approving, executing, or performing research under a CRADA or non-federal SPP.

    Significant Financial Interest

    Financial Interest means a financial interest consisting of one or more of the following interests of the investigator or the investigator's spouse or registered domestic partner* and dependent children for the following categories, except in the case of travel:

    1. With regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. Included are consulting fees, honoraria, gifts, and the equity interest value at the date of disclosure as determined by public prices or other reasonable measures of fair market value.
    2. With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the investigator holds any equity interest.
    3. Intellectual property rights and interests, upon receipt of income, exceeding $5,000 during the twelve months preceding disclosure from such rights and interests. However, significant financial interests do not include royalties received from the University of California Regents.
    4. In the case of travel, sponsored travel or reimbursements made to or on behalf of the investigator, regardless of the amount, by a for-profit or non-profit entity related to the investigator's institutional responsibilities. However, significant financial interests do not include travel reimbursed or paid by a federal, state, or local government agency, a U.S. institution of higher education, or a research institute, academic medical center, or hospital affiliated with an institution of higher education.1

      *The inclusion of "registered domestic partner" is consistent with California State law (Family Code, section 297 et seq.).

    The term "significant financial interest" does not include the following types of financial interests:

      • Salary, royalties, or other payments paid by the University of California Regents to a University or Laboratory investigator who is currently employed or otherwise appointed by the Laboratory or University.
      • Income from seminars, lectures, teaching engagements, or service on advisory committees or review panels sponsored by a federal, state, or local government; an agency; a U.S. institution of higher education; or a research institute, academic medical center, or hospital affiliated with an institution of higher education.2
      • Income from investment vehicles, such as mutual funds and retirement funds, in which the investigator does not directly control investment decisions.

        1,2 These references refer to a U.S. institution of higher education or a federal, state, or local government agency within the United States. Therefore, Investigators, including subrecipient Investigators, must disclose all financial interests received from a foreign institution of higher education or the government of another country (which includes local, provincial, or equivalent governments of another country). 

    Financial Conflict of Interest

    A situation in which an Investigator or the Investigator’s spouse or dependent children has a significant financial interest or financial relationship that could directly and significantly affect the design, conduct, reporting or funding of a project.

    G. Recordkeeping Requirements

    None

    H. Implementing Documents

    I. Contact Information

    Research Compliance Office

    [email protected]

    Revision History

    Date

    Revision

    By Whom

    Revision Description

    Section(s) Affected

    Change Type

    1/2/2012

    0

    M. Stoufer

    Rewrite for wiki (brief)

    All

    Minor

    9/25/2012

    1

    M. Stoufer

    Rewrite for wiki (policy)

    All

    Minor

    7/8/2020 1.1 M. Stoufer Update source requirements, contact information, office names All Minor
    12/16/2020
    D. Soustin Updated Contract 31 I clause numbers as per mod 1105 SRDs Editorial
    12/11/2025 2 M. Stoufer

    Periodic review: updated to combine CRADA, SPP and 700-U requirements based on C31 Mod 1155 update to clause I.138. Merged with the Conflict of Interest in Research – Private Sponsors policy. Policy name changed from COI - CRADAs to COI - CRADAs and non Federal SPPs.

    All

    Major

    DOCUMENT INFORMATION

    Title:

    Conflict of Interest in Research – CRADAs and non-Federal SPPs

    Document number

    05.02.003.000

    Revision number

    2

    Publication date:

    12/11/2025

    Effective date:

    12/11/2025

    Next review date:

    12/10/2030

    Policy Area:

    COI in Research

    RPM Section (home)

    Conflict of Interest

    RPM Section (cross-reference)

    Non-DOE Funded Research

    Functional Division

    Research Compliance Office

    Prior reference information (optional)

    Section 10.08

    Source Requirements Documents



    • No labels